Telehealth model of care for outpatient inflammatory bowel disease care in the setting of the COVID-19 pandemic
- PMID: 34278693
- PMCID: PMC8444910
- DOI: 10.1111/imj.15168
Telehealth model of care for outpatient inflammatory bowel disease care in the setting of the COVID-19 pandemic
Abstract
Background: Advances in inflammatory bowel disease (IBD) monitoring, greater number of available treatments and a shift towards tight disease control, IBD care has become more dynamic with regular follow ups.
Aims: We assessed the impacts of the COVID-19 pandemic on outpatient IBD patient care at a tertiary centre in Melbourne. More specifically, we assessed patient satisfaction with a telehealth model of care, failure to attend rates at IBD clinics and work absenteeism prior to and during the pandemic.
Methods: We conducted a retrospective, qualitative analysis to assess our aims through an online survey. We invited patients who attended an IBD outpatient clinic from April to June 2020 to participate. This study was conducted at a single, tertiary referral hospital in Melbourne. The key data points that we analysed were patient satisfaction with a telehealth model of care and the effect of telehealth clinics on work absenteeism.
Results: One hundred and nineteen (88.1%) patients were 'satisfied' or 'very satisfied' with the care received in the telehealth clinic. Eighty-four (60.4%) patients reported needing to take time off work to attend a face-to-face appointment, compared to 29 (20.9%) patients who needed to take time off work to attend telehealth appointments (P < 0.001). Clinic non-attendance rates were similar prior to and during the pandemic with rates of 11.4% and 10.4% respectively (P = 0.840).
Conclusions: Patients report high levels of satisfaction with a telehealth model of care during the COVID-19 pandemic, with clinic attendance rates not being affected. Telehealth appointments significantly reduced work absenteeism when compared to traditional face-to-face clinics.
Keywords: COVID-19; inflammatory bowel disease; outpatient clinic; telehealth.
© 2021 Royal Australasian College of Physicians.
Figures
References
-
- Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EIet al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population‐based studies. Lancet 2017; 390: 2769–78. - PubMed
-
- Ahmed Z, Sarvepalli S, Garber A, Regueiro M, Rizk MK. Value‐based health care in inflammatory bowel disease. Inflamm Bowel Dis 2019; 25: 958–68. - PubMed
-
- D'Haens GR. Top‐down therapy for IBD: rationale and requisite evidence. Nat Rev Gastroenterol Hepatol 2010; 7: 86–92. - PubMed
-
- Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Vaňásek Tet al. Effect of tight control management on Chrohn's disease (CALM): a multicentre, randomized, controlled phase 3 trial. Lancet 2018; 390: 2779–89. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous